Jcovden (previously COVID-19 Vaccine Janssen)

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S)

Available from:

Janssen-Cilag International NV

ATC code:

J07BN02

INN (International Name):

COVID-19 vaccine (Ad26.COV2-S [recombinant])

Therapeutic group:

Cepiva

Therapeutic area:

COVID-19 virus infection

Therapeutic indications:

Jcovden is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. Uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

Product summary:

Revision: 30

Authorization status:

Pooblaščeni

Authorization date:

2021-03-11

Patient Information leaflet

                                28
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA -
1.
IME ZDRAVILA
JCOVDEN suspenzija za injiciranje
cepivo proti COVID-19 (Ad26.COV2-S [rekombinantno])
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
En odmerek (0,5 ml) vsebuje najmanj 8,92 log
10
infektivnih enot.
adenovirus tipa 26, ki kodira glikoprotein bodice virusa SARS-CoV-2
(Ad26.COV2-S)
Cepivo vsebuje gensko spremenjene organizme.
3.
SEZNAM POMOŽNIH SNOVI
Pakiranje z 10 vialami
Pomožne snovi: 2-hidroksipropil-β-ciklodekstrin, citronska kislina
monohidrat, etanol, klorovodikova
kislina, polisorbat-80, natrijev klorid, natrijev hidroksid,
trinatrijev citrat dihidrat, voda za injekcije. Za
več podatkov glejte navodilo za uporabo.
Pakiranje z 20 vialami
Pomožne snovi: 2-hidroksipropil-β-ciklodekstrin, citronska kislina
monohidrat, etanol, klorovodikova
kislina, polisorbat-80, natrijev klorid, natrijev hidroksid, voda za
injekcije. Za več podatkov glejte
navodilo za uporabo.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
suspenzija za injiciranje
10 večodmernih vial
20 večodmernih vial
Ena viala vsebuje 5 odmerkov po 0,5 ml.
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
intramuskularna uporaba
Pred uporabo preberite priloženo navodilo!
Za več podatkov poskenirajte QR kodo ali obiščite spletno stran
www.covid19vaccinejanssen.com.
29
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
Glejte EXP za datum izteka roka uporabnosti pri temperaturi od -25 °C
do -15 °C.
Zapišite nov datum izteka roka uporabnosti za shranjevanje pri
temperaturi od 2 °C do 8 °C (za največ
11 mesecev):______________. Ko zapišete nov datum izteka roka
uporabnosti, prvotni datum
prečrtajte.
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte in prevažajte zamrznjeno pri temperaturi od -25 °C do -15
°C.
Cepivo se lahko 11 mesecev shranjuje tudi pri temperaturi od 2 °C do
8 °C. Zapišite nov datum izteka
roka uporabnosti.
Po odtalitvi cepiva ne smete ponovno zamrzniti.
Viale shranjujte v škatli za zagot
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
Za to zdravilo se izvaja dodatno spremljanje varnosti. Tako bodo
hitreje na voljo nove informacije
o njegovi varnosti. Zdravstvene delavce naprošamo, da poročajo o
katerem koli domnevnem
neželenem učinku zdravila. Glejte poglavje 4.8, kako poročati o
neželenih učinkih.
1.
IME ZDRAVILA
JCOVDEN suspenzija za injiciranje
cepivo proti COVID-19 (Ad26.COV2-S [rekombinantno])
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
To je večodmerna viala, ki vsebuje 5 odmerkov po 0,5 ml.
En odmerek (0,5 ml) vsebuje:
adenovirus tipa 26, ki kodira glikoprotein bodice virusa SARS-CoV-2*
(Ad26.COV2-S), v količini
najmanj 8,92 log
10
infektivnih enot (Inf.U).
*
pridobljen v celični liniji PER.C6 TetR s tehnologijo rekombinantne
DNK
Cepivo vsebuje gensko spremenjene organizme (GSO).
Pomožne snovi z znanim učinkom
En odmerek (0,5 ml) vsebuje približno 2 mg etanola.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
suspenzija za injiciranje (injekcija)
brezbarvna do rahlo rumena, bistra do močno opalescentna suspenzija
(pH 6-6,4)
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Cepivo JCOVDEN je indicirano za aktivno imunizacijo za preprečevanje
bolezni COVID-19, ki jo
povzroča virus SARS-CoV-2, pri posameznikih, starih 18 let in več.
To cepivo je treba uporabljati v skladu z uradnimi priporočili.
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
_Posamezniki, stari 18 let in več_
Primarno cepljenje
Cepivo JCOVDEN se daje v enkratnem odmerku 0,5 ml samo z
intramuskularno injekcijo.
3
Poživitveni odmerek
Poživitveni odmerek (drugi odmerek) cepiva JCOVDEN se lahko daje
intramuskularno v odmerku
0,5 ml vsaj 2 meseca po primarnem cepljenju pri posameznikih, starih
18 let ali več (glejte tudi
poglavja 4.4, 4.8 in 5.1).
Poživitveni odmerek cepiva JCOVDEN (0,5 ml) se lahko pri
posameznikih, starih 18 let ali več, daje
kot heterologni poživitveni odmerek po zaključku primarnega
cepljenja z mRNK cepivom proti
COVID-19 ali z adenovirusnim vektorskim cepivom p
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 26-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 26-03-2024
Public Assessment Report Public Assessment Report Bulgarian 04-07-2023
Patient Information leaflet Patient Information leaflet Spanish 26-03-2024
Public Assessment Report Public Assessment Report Spanish 04-07-2023
Patient Information leaflet Patient Information leaflet Czech 26-03-2024
Public Assessment Report Public Assessment Report Czech 04-07-2023
Patient Information leaflet Patient Information leaflet Danish 26-03-2024
Public Assessment Report Public Assessment Report Danish 04-07-2023
Patient Information leaflet Patient Information leaflet German 26-03-2024
Public Assessment Report Public Assessment Report German 04-07-2023
Patient Information leaflet Patient Information leaflet Estonian 26-03-2024
Public Assessment Report Public Assessment Report Estonian 04-07-2023
Patient Information leaflet Patient Information leaflet Greek 26-03-2024
Public Assessment Report Public Assessment Report Greek 04-07-2023
Patient Information leaflet Patient Information leaflet English 26-03-2024
Public Assessment Report Public Assessment Report English 04-07-2023
Patient Information leaflet Patient Information leaflet French 26-03-2024
Public Assessment Report Public Assessment Report French 04-07-2023
Patient Information leaflet Patient Information leaflet Italian 26-03-2024
Public Assessment Report Public Assessment Report Italian 04-07-2023
Patient Information leaflet Patient Information leaflet Latvian 26-03-2024
Public Assessment Report Public Assessment Report Latvian 04-07-2023
Patient Information leaflet Patient Information leaflet Lithuanian 26-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 26-03-2024
Public Assessment Report Public Assessment Report Lithuanian 04-07-2023
Patient Information leaflet Patient Information leaflet Hungarian 26-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 26-03-2024
Public Assessment Report Public Assessment Report Hungarian 04-07-2023
Patient Information leaflet Patient Information leaflet Maltese 26-03-2024
Public Assessment Report Public Assessment Report Maltese 04-07-2023
Patient Information leaflet Patient Information leaflet Dutch 26-03-2024
Public Assessment Report Public Assessment Report Dutch 04-07-2023
Patient Information leaflet Patient Information leaflet Polish 26-03-2024
Public Assessment Report Public Assessment Report Polish 04-07-2023
Patient Information leaflet Patient Information leaflet Portuguese 26-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 26-03-2024
Public Assessment Report Public Assessment Report Portuguese 04-07-2023
Patient Information leaflet Patient Information leaflet Romanian 26-03-2024
Public Assessment Report Public Assessment Report Romanian 04-07-2023
Patient Information leaflet Patient Information leaflet Slovak 26-03-2024
Public Assessment Report Public Assessment Report Slovak 04-07-2023
Patient Information leaflet Patient Information leaflet Finnish 26-03-2024
Public Assessment Report Public Assessment Report Finnish 04-07-2023
Patient Information leaflet Patient Information leaflet Swedish 26-03-2024
Public Assessment Report Public Assessment Report Swedish 04-07-2023
Patient Information leaflet Patient Information leaflet Norwegian 26-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 26-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 26-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 26-03-2024
Patient Information leaflet Patient Information leaflet Croatian 26-03-2024
Public Assessment Report Public Assessment Report Croatian 04-07-2023